logo
 

INTERACTIVE
WEBINAR

 
Call-in teleconferencing 
 
Video demonstrations included in the presentation
 
 
 
VIEW ALL WEBINARS 
 
610-399-4897
 

 

 

 
 

HOW TO AVOID  483’s AND SAVE MONEY IN MULTIPRODUCT FACILITIES

November 20, 2009 WEBINAR
Noon-1:30 pm EST
Companies with Multiproduct facilities are at risk from the regulator, the FDA has cut the response time to 483’s to 15 days before enforcement action can proceed. This seminar looks at these risks and how to face them. The trouble is that in the main both sides use perception qualitative statements that are not based in science. This seminar reviews these issues and shows how much current thinking in facility design leads to unnecessary cost for no demonstrable benefit.
 
The talk is illustrated by data gained over many projects.

In this webinar you will learn about:

·     Major Causes of Observation
·     Why this is a vital topic
·     Regulatory Issues
·     Quality
·     FDA’s Six Systems of Control
·     Major causes of observations
·     Risk, Hazard and Exposure
·     Variables to be Controlled
·     Facilities:  Upgrades and Energy Costs
·     Facility Design Concepts
·     HVAC :  What Works and Doesn’t Work
·     Airlocks :  Essential or Costly and Unnecessary
·     Engineering Controls and Over Engineering
·     Process Integration
·     Ergonomics and Material Handling
·     Mix Up and Why it is a Cause of Observations
·     Quality Risk Management Plans

·     QRMP

Instructor:  Julian Wilkins Dip, Arch. (Oxford) RIBA, VP PharmaConsult US, Inc, Adjunct Professor Stevens Institute
Julian Wilkins is founder and vice president with PharmaConsult US, Inc. In 1991 he founded a UK based isolator company for the emerging need for pharmaceutical containment. The company carried out many projects worldwide for aseptic and potent containment at all scales of pharmaceutical operation. He moved to the US in 1997 and set up PharmaConsult US in 1999. Since its formation, the company has provided independent advice, design and support for containment projects including Bristol-Myers Squibb, Chiron, GSK, Merck & Co., Pfizer, Roche Colorado, Sanofi Sythelabo, Tyco/ Mallinckrodt and Wyeth. Wilkins is a past recipient of the prestigious ISPE Member of the Year award. Mr. Wilkins has spoken at many seminars worldwide on the subject of containment and has contributed articles and chapters to periodicals and books on containment.
 
 
 FEE: $345 for one person.
Call for special per person discounts for multiple participants from your company.
610-399-4897
 
ECCWEB141